in
  1. Preventive regulations. Healthcare.gov web site. www.healthcare.gov/center/regulations/prevention/regs.html.
  2. US Preventive Services Task Force web site. www.uspreventiveservicestaskforce.org/index.html.
  3. What are the key statistics for prostate cancer? American Cancer Society web site. http://www.cancer.org/cancer/prostatecancer/detailedguide/prostate-cancer-key-statistics. Updated November 2010.
  4. Greene KL, Albertsen PC, Babaian RJ, et al. Prostate specific antigen best practice statement: 2009 update. J Urol 2009; 182:2232 [Abstract]
  5. National Cancer Institute fact sheet: prostate specific antigen test. National Cancer Institute web site. http://www.cancer.gov/cancertopics/factsheet/detection/PSA. Reviewed March 18, 2009.
  6. Wolf AM, Wendner RC, Etzioni RB. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin 2010; 60:70. [Full text]
  7. Djulbegovic M, Beyth RJ, Neuberger MM. Screening for prostate cancer: systematic review and meta-analysis of randomized controlled trials. BMJ 2010; 341:c4543. [Full text]
  8. What are the risk factors for prostate cancer? American Cancer Society web site. www.cancer.org/Cancer/ProstateCancer/DetailedGuide/prostate-cancer-risk-factors. Updated November 22, 2010.
  9. Barry MJ. Screening for prostate cancer—the controversy that refuses to die. N Engl J Med 2009; 360:1351. [Full text]
  10. US Preventive Services Task Force. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. Ann Intern Med 2008; 149:185. [Full text]
  11. Pinsky PF, Andriole G, Crawford ED, et al. Prostate-specific antigen velocity and prostate cancer gleason grade and stage. Cancer 2007; 109:1689. [Full text]
  12. Lee R, Localio AR, Armstrong K, et al. A meta-analysis of the performance characteristics of the free prostate-specific antigen test. Urology 2006; 67:762.[Abstract]
  13. Horninger W, Cheli CD, Babaian RJ, et al. Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter. Urology 2002; 60:31.[Abstract]
  14. Partin AW, Brawer MK, Bartsch G, et al. Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial. J Urol 2003; 170:1787.[Abstract]
  15. Tanguay S, Bégin LR, Elhilali MM, et al. Comparative evaluation of total PSA, free/total PSA, and complexed PSA in prostate cancer detection. Urology 2002; 59:261.[Abstract]
  16. Schroder FH, Hugosson J, Roobol MJ. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360:1320. [Full text]
  17. Bastian PJ, Carter BH, Bjartell A, et al. Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur Urol 2009; 55:1321. [Abstract]
  18. Nagler HM, Gerber EW, Homel P, et al. Digital rectal examination is barrier to population-based prostate cancer screening. Urology 2005; 65:1137. [Abstract]
  19. American Cancer Society. Cancer Facts & Figures 2010. Atlanta, GA: American Cancer Society, Inc. 2010. [PDF]
Copyright © 2010, 2011  Perelman School of Medicine at the University of Pennsylvania Office of Continuing Medical Education & BestPractice CPD, LLC®. All rights reserved.